Endotracheal cuff and technique for using the same

Information

  • Patent Grant
  • 7950393
  • Patent Number
    7,950,393
  • Date Filed
    Friday, September 29, 2006
    18 years ago
  • Date Issued
    Tuesday, May 31, 2011
    13 years ago
Abstract
An inflatable balloon cuff associated with a tracheal tube may be adapted to filter microbial secretions and reduce their passage into the lungs. A cuff as provided may include a cross-linked polymeric structure that may serve to exclude certain secretions on the basis of size. The polymeric structure may be incorporated onto all or part of the surface of the inflatable balloon cuff.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to medical devices, and more particularly, to airway products, such as tracheal tubes and cuffs.


2. Description of the Related Art


This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present invention, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present invention. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.


In the course of treating a patient, a tube or other medical device may be used to control the flow of air, food, fluids, or other substances into and/or out of the patient. For example, medical devices such as tracheal tubes may be used to control the flow of one or more substances into or out of a patient. In many instances it is desirable to provide a seal between the outside of the tube or device and the interior of the passage in which the tube or device is inserted. In this way, substances can only flow through the passage via the tube or other medical device, allowing a medical practitioner to maintain control over the type and amount of substances flowing into and out of the patient.


For example, tracheal tubes may be used to control the flow of air or other gases through a patient's trachea. Such tracheal tubes may include endotracheal (ET) tubes or tracheostomy tubes. To seal these types of tracheal tubes, an inflatable cuff may be associated with these tubes. When inflated, the cuff generally expands into the surrounding trachea to seal the tracheal passage around the tube.


However, to fit a range of trachea anatomies and to provide low intra cuff pressure, cuff diameters are typically about one and a half times the diameter of the average trachea. Therefore, when inserted in an average-sized trachea, such a cuff is unable to fully expand and will fold in on itself within the trachea. These folds may serve as leak paths that allow mucosal secretions to flow past the cuff and enter the lung. Because mucosal secretions may harbor microbes, it is desirable to prevent such secretions from entering the lungs.


Certain types of cuffs are manufactured from materials that have a lower tendency to form leak paths. For example, high pressure cuffs are typically made of highly elastic materials that may form a relatively smooth seal against the trachea. However, such cuffs have associated disadvantages. Due to their elastic properties, high pressure cuffs are often inflated to at least twice the intracuff pressure of lower pressure cuffs in order to form a sufficient tracheal seal. Such high pressures may cause patient discomfort. Further, the mechanical pressure of the high pressure cuff against the tracheal walls may also cause temporary damage to cilial structures in the trachea that are associated with airway particle clearance.


Other types of cuffs may include swellable layers that may be involved in providing a physical barrier to fill the leak paths. However, such physical barriers may be nonetheless permeable to microbial infiltration. For example, such cuffs may employ a hydrogel that may swell into the folds of the cuff. However, many hydrogel coatings may be too porous to prevent the microbes in mucosal secretions from flowing through leak paths in the cuff. Further, many hydrogel coatings are dynamic in nature, with constantly changing pore sizes.


SUMMARY

Certain aspects commensurate in scope with the originally claimed invention are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the invention might take and that these aspects are not intended to limit the scope of the invention. Indeed, the invention may encompass a variety of aspects that may not be set forth below.


There is provided a medical device that includes an inflatable balloon cuff; and a filtration layer having a pore size of less than 5 microns disposed on a tissue-contacting surface of the balloon cuff.


There is also provided a method of manufacturing a medical device that includes providing an inflatable balloon cuff; and providing a filtration layer having a pore size of less than 5 microns disposed on a tissue-contacting surface of the balloon cuff.


There is also provided a method of sealing a patient's trachea that includes inserting an inflatable balloon cuff into a patient's trachea; applying a monomer solution to a surface of the balloon cuff; and cross-linking the monomer solution to produce a filtration layer having a pore size of less than 5 microns.


There is also provided a medical device that includes: an inflatable balloon cuff; and a filtration layer disposed on a tissue-contacting surface of the balloon cuff, wherein the filtration layer is adapted to filter out microbes from mucosal secretions.


There is also provided a method that includes: filtering out microbes from mucosal secretions before they enter the folds of an inflatable balloon cuff.





BRIEF DESCRIPTION OF THE DRAWINGS

Advantages of the invention may become apparent upon reading the following detailed description and upon reference to the drawings in which:



FIG. 1 illustrates an endotracheal tube with an inflatable balloon cuff with a filtration layer in accordance with aspects of the present technique;



FIG. 2 illustrates the inflatable balloon cuff of the present techniques inserted into a patient's trachea;



FIG. 3 illustrates a cross-sectional view of the filtration layer applied to an endotracheal cuff;



FIG. 4 illustrates an exemplary cuff wrinkle with a filtration layer forming a vertical filtration channel;



FIG. 5 illustrates an alternative inflatable balloon cuff with a filtration layer disposed on the top of the cuff; and



FIG. 6 illustrates a modified endotracheal tube with a lumen adapted to deliver a filtration layer to an inflatable balloon cuff.





DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS

One or more specific embodiments of the present invention will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.


In accordance with some aspects of the present technique, an inflatable cuff is provided that includes a filtration layer that is adapted to filter mucosal secretions before the secretions travel down any folds in the cuff and into the lungs. The filtration layer may be characterized as having a limited pore size that is able to filter out microbes. It is desirable to provide a medical balloon, such as an endotracheal cuff or other medical device, which may substantially seal the passage in which the cuff is inserted so that mechanical ventilation can be used to introduce air, oxygen, or medications into the lungs. As cuffs are typically sized to be larger than the trachea when fully inflated in order to effectively seal a wide range of patient tracheas, the cuff walls are unable to inflate to their maximum diameter and may fold in on themselves, which may cause wrinkles and leak paths to form. These leak paths may be conduits for microbes, for example those found in mucosal secretions, to travel into to lungs. The cuffs including filtration layers, as provided herein, may filter out microbes from the mucosal secretions that enter cuff leak paths to travel into the lungs.


A filtration layer may be any suitable material having a pore size smaller than the microbes that are being filtered. As most bacteria have diameters that are microns in scale, a suitable pore size may be on the lower end of the micron scale in order to filter out most bacteria. Many microbes fall into the size range of 0.2-20 microns. In certain embodiments, microbes fall into the size range of 3-5 microns. Exemplary microbes to be filtered include Puedomonas aeruginosa, Staphylococcus aureus, Enterobacter spp, Haemophilus influenza, Streptococcus spp, Candida ablicans (yeast), Stenotrophomonas multiphilia, Methicillin Resistant Staphyloccus aureus, and others, including viruses. In certain embodiments, an appropriate pore size for the filtration layer is less than 5 microns or less than 2 microns. In other embodiments, the pore size may be less than 0.2 microns in order to filter out the broadest range of microbes. Further, as certain microbes may be capable of changing morphology under pressure in order to “squeeze” through pores having a slightly smaller diameter, a pore size of less than 0.2 microns may be advantageous as such a size may generally be substantially smaller than most bacteria. Pore size may be defined as the average diameter, or a range of diameters, of the individual pores in a membrane. Generally, pore size may be determined statistically by the average dimension of the smallest particle that will pass through the material. Several standardized tests are available to determine pore size. For example, the bubble point test is evaluates performance under aqueous conditions. Pore size may also be calculated from measurements of capillary force, pressure, and water height. One such method is described in ASTM F 316.


The medical cuffs as provided herein may be used in conjunction with any suitable medical device. In certain embodiments, the cuffs as provided herein may be used in conjunction with a catheter, a stent, a feeding tube, an intravenous tube, an endotracheal tube, a tracheostomy tube, a circuit, an airway accessory, a connector, an adapter, a filter, a humidifier, a nebulizer, or a prosthetic, in various embodiments.


An example of a cuff used in conjunction with a medical device is a cuffed endotracheal tube 10, depicted in FIG. 1. The cuffed endotracheal tube 10 includes an inflatable cuff 12 that may be inflated to form a seal against the trachea wall 28 (see FIG. 2). In certain embodiments, the cuff 12 includes a filtration layer 14 that is disposed over the outer surface of the cuff 12. The cuff is disposed on an endotracheal tube 16 that is suitably sized and shaped to be inserted into a patient and allow the passage of air through the endotracheal tube 16. Typically, the cuff is disposed, adhesively or otherwise, towards the distal end 17 of the endotracheal tube 16. The cuff 12 may be inflated and deflated via a lumen 15 in communication with the cuff 12, typically through a hole or notch in the lumen 15. The cuff 12 has a proximal opening 20 and a distal opening 22 formed in the cuff walls sized to accommodate the endotracheal tube 16. The proximal opening 20, located closer to the “machine end” of the tube 16, and a distal opening 22, located closer to the “patient end” of the tube 16, are typically used to mount the cuff 12 to the tube 16.


The cuff 12 may be formed from materials having suitable mechanical properties (such as puncture resistance, pin hole resistance, tensile strength), chemical properties (such as forming a suitable bond to the tube 16), and biocompatibility. In one embodiment, the walls of the inflatable cuff 12 are made of a polyurethane having suitable mechanical and chemical properties. An example of a suitable polyurethane is Dow Pellethane® 2363-80A. In another embodiment, the walls of the inflatable cuff 12 are made of a suitable polyvinyl chloride (PVC). Other suitable materials include polypropylene, polyethylene teraphthalate (PETP), low-density polyethylene (LDPE), silicone, neoprene, or polyisoprene.


The filtration layer 14 is configured to be disposed on the outer, tissue-contacting surface of the cuff 12. The filtration layer 14 reduces or prevents the passage of microbes larger than a certain size. FIG. 2 shows the exemplary cuffed endotracheal tube 10 inserted into a patient's trachea. As depicted, the filtration layer 14 may directly contact mucosal tissue that is involved in producing secretions that may travel into the lungs. The cuff 12 is inflated to form a seal against the tracheal walls 28 such that the filtration layer 14 is in contact with the mucosal tissue. Thus, mucosal secretions 30 encounter the filtration layer 14 before they pass through the trachea into the lungs, as depicted in FIG. 3. The small pore size of the filtration layer 14 prevents the progress of particles larger in the mucosal secretions that are larger than a certain size but still allows the liquid phase to pass through.


Further, the filtration layer 14 may be disposed on the cuff 12 such that as the cuff 12 folds in on itself to form wrinkles 25, the filtration layer 14 creates a vertical channel down the wrinkle 25. In such an embodiment, the filtration layer 14 may be a few microns to several millimeters in thickness in order to fill the fold of the cuff, depending on how the cuff 12 folds. In certain embodiments, it may be advantageous to use a filtration layer 14 that may have a surface treatment or charge, such that the folds of the cuff 12 will be attracted to one another to encourage formation of the vertical channel. For example, a polymer filtration layer 14 may be formed from cross-linked amphipathic polymers such as having hydrophilic branches and a hydrophobic backbone that may adhere easily to a hydrophobic cuff 12. In alternative embodiments, the filtration layer 14 may undergo a surface treatment, such as plasma treatment, in order to modify its surface characteristics. Further, a hydrophilic filtration layer 14 may also encourage formation of a seal of the cuff walls against the mucosal tissue, which is generally hydrophilic in nature.


In other embodiments, the filtration layer 14 may be disposed on only a portion of the cuff 12. The filtration layer 14 may be disposed on the cuff such that it creates a barrier to microbial entry into any wrinkles 25. Shown in FIG. 5 is a cuff 12 with a filtration layer 14 disposed on the top of the cuff 12. When a cuff 12 is inflated into a patient's trachea, the area of the cuff 12 near the proximal opening 20 of the cuff walls may form a relatively flat surface that may tend to collect mucosal secretions. Although these secretions may be periodically aspirated, their collective pressure and weight between aspiration events may tend to accelerate the flow of secretions down the leak paths created by the wrinkles 25. The filtration layer 14 may filter out microbes and larger particles from the secretions before they may enter the wrinkles 14. The filtration layer 14 may be applied to the top of the cuff 12 prior to insertion of the tube 10 into the trachea. Alternatively, the filtration layer may be applied to the cuff 12 after insertion of the tube into the trachea. For example, an endotracheal tube 10a is depicted in FIG. 6. The tube 10a includes a lumen 32 that is adapted to deliver a filtration layer 14 to the area of the cuff 12 near the proximal opening 20. The lumen 32 may also deliver a precursor fluid that may be processed after application to the cuff 12 in order to form the filtration layer 14 in situ. In such an embodiment, the fluid delivered by the lumen 32 should be substantially biocompatible. For example, an amide monomer solution may be delivered through the lumen 32 to the cuff 12 and cross-linked in place by adding a peroxide initiator.


The filtration layer 14 may be any suitable material with an appropriate pore size. For example, the filtration layer 14 may be a microporous polymer or polymer mixture. The pore size of the polymer mixture may be adjusted by increased cross-linking of the polymer. For example, the filtration layer 14 may include a microporous polypropylene blend. Such a microporous polymer may be fabricated by compounding a polypropylene major phase system of less than 15% total weight with a polystyrene minor phase as detailed in “Preparation of Microporous Films from Immiscible Blends via Melt Processing,” Chandavasu, et al. Journal of Plastic Film and Sheeting, Vol. 16, No. 4, 288-300 (2000). Alternatively, the filtration layer 14 may be a polyacrylamide polymer network. The acrylamide polymerization solution may be a 4-5% solution (acrylamide/bisacrylamide 19/1) in water/glycerol, with a nominal amount of initiator added. The solution may be polymerized and cross-linked either by ultraviolet radiation or by thermal initiation at elevated temperature. The pore size of the gel may be controlled by changing the amount of crosslinker and the percent of solids in the monomer solution. The cuff 12 may be dipped into the polyacrylamide solution, and removed before initiation of cross-linking. The solution characteristics and dip times may be adjusted, depending on the desired thickness of the filtration layer 14. Polyethyleneimine, polyacrylamide, polymers of dimethylaminoethylmethacrylate, polymers of ammonio methacrylate, and copolymers of dimethylaminoethylmethacrylate and ammonio methacrylate. Alternatively, the filtration layer 14 may be an interpenetrating polymer network, such as a hydrogel network. The pore size of such networks may be controlled through the amount of cross-linking as well as through the monomer or oligomer size.


The filtration layer 14 may also be a homogeneous hydrogel. Such a hydrogel may be polymerized to have the appropriate microporosity through bulk polymerization, i.e. polymerization in the absence of added solvent. Bulk polymerization of a homogeneous hydrogel initially produces a glassy, transparent polymer matrix that is relatively hard. When immersed in water, the glassy matrix swells to become soft and flexible. Although it permits the transfer of water and some low-molecular-weight solutes, such a swollen polymer matrix hydrogel is considered non-porous. The pores between polymer chains are in fact the only spaces available for the mass transfer, and the pore size is within the range of molecular dimensions (a few nanometers or less). Suitable hydrogel monomers may include polyethylene glycol and methacrylic acid.


The distance between crosslinks, or crosslink density, is a critical factor in determining the pore size of a hydrogel “filter”. The crosslink density can be controlled by factors such as the crosslinking agent concentration, the molecular weight of the crosslinker, and the state of the hydrogel during the crosslinking process. For instance, the amount the hydrogel is swollen during the crosslinking process will have a large impact on the potential swelling of the final hydrogel. This is due to the distance between the polymer chains under different solvent conditions during the crosslinking process. Because of the high percentage of swelling that occurs in hydrogels, it is possible for hydrogels pressed together to intermingle and achieve molecular entanglement. This helps provide a filtering mechanism in the folds that form along the cuff 12 after inflation within the trachea. In this way, a contiguous microbe filter can be achieved.


In another specific embodiment, the filtration layer 14 may be a layer formed from small peptides with the characteristics of self-assembling into a film, such as those detailed in U.S. Pat. No. 7,098,028. For example, the peptide EAK16 (AEAEAKAKAEAEAKAK) self-assembles into stable macroscopic membranes in the presence of millimolar concentrations of salt. Peptides having these properties participate in intermolecular interactions which result in the formation and stabilization of beta-sheets at the secondary structure level and interwoven filaments at the tertiary structure level.


A variety of manufacturing techniques can be used to apply the filtration layer 14 to the cuff 12. For example, the cuff 12 can be dipped into a solution containing monomers that may be polymerized on the cuff 12. In other embodiments, the filtration layer 14 may be co-extruded with the cuff 12 or may be molded, co-extrusion blow-molded, electrostatically applied, extruded and applied to a balloon blowing apparatus, or sprayed.


The tracheal cuffs of the present techniques may be incorporated into systems that facilitate positive pressure ventilation of a patient, such as a ventilator. Such systems may typically include connective tubing, a gas source, a monitor, and/or a controller. The controller may be a digital controller, a computer, an electromechanical programmable controller, or any other control system.


Typically, endotracheal cuffs are inflated within a patient's trachea such that the intra cuff pressure is approximately 20-25 cm H2O. Endotracheal cuffs utilizing inflation pressures significantly greater 50 cm H2O may be referred to as high-pressure cuffs, while cuffs that are able to effectively seal the trachea at pressures less than 30 cm H2O may be considered low-pressure cuffs. In certain embodiments, intra cuff inflation pressures of 10-30 cm H2O may be used with the cuffs of the present techniques.


While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.

Claims
  • 1. A medical device comprising: an inflatable balloon cuff;a tracheal tube associated with the balloon cuff, wherein the tracheal tube passes through an opening of the balloon cuff; anda filtration layer having a pore size of less than 5 microns disposed on a tissue-contacting surface of the balloon cuff.
  • 2. The medical device, as set forth in claim 1, wherein the filtration layer has a pore size of less than 0.2 microns.
  • 3. The medical device, as set forth in claim 1, wherein the filtration layer is at least 0.0002 inches in thickness.
  • 4. The medical device, as set forth in claim 1, wherein the balloon cuff comprises polyethylene teraphthalate (PETP), low-density polyethylene (LDPE), polyvinyl chloride (PVC), silicone, neoprene, polyisoprene, or polyurethane (PU).
  • 5. The medical device, as set forth in claim 1, comprising a ventilator to which the endotracheal tube is operatively connected.
  • 6. The medical device, as set forth in claim 1, wherein the filtration layer is cross-linked.
  • 7. The medical device, as set forth in claim 1, wherein filtration layer comprises a hydrogel.
  • 8. The medical device, as set forth in claim 1, wherein the filtration layer comprises an interpenetrating polymer network.
  • 9. The medical device, as set forth in claim 1, wherein the filtration layer comprises a peptide protein network.
  • 10. The medical device, as set forth in claim 1, wherein the filtration layer comprises at least one of polyethyleneimine, polyacrylamide, dimethylaminoethylmethacrylate, ammonio methacrylate, or any combination thereof.
  • 11. A method of manufacturing a medical device, comprising: providing an inflatable balloon cuff;providing an endotracheal tube associated with the balloon cuff, wherein the endotracheal tube passes through an opening of the balloon cuff; andproviding a filtration layer having a pore size of less than 5 microns disposed on a tissue-contacting surface of the balloon cuff.
  • 12. The method, as set forth in claim 11, wherein providing the filtration layer comprises providing a layer at least 0.0002 inches in thickness.
  • 13. The method, as set forth in claim 11, comprising providing a ventilator to which the endotracheal tube is operatively connected.
  • 14. The method, as set forth in claim 11, wherein providing the filtration layer comprises providing a cross-linked layer.
  • 15. The method, as set forth in claim 11, wherein providing the filtration layer comprises providing a hydrogel.
  • 16. The method, as set forth in claim 11, wherein providing the filtration layer comprises providing an interpenetrating polymer network.
  • 17. The method, as set forth in claim 11, wherein providing the filtration layer comprises providing a protein network.
  • 18. The method, as set forth in claim 11, wherein providing the filtration layer comprises providing at least one of polyethyleneimine, polyacrylamide, dimethylaminoethylmethacrylate, ammonio methacrylate, or any combination thereof.
  • 19. A method of sealing a patient's trachea, comprising: inserting an inflatable balloon cuff into a patient's trachea;applying a monomer solution to a surface of the balloon cuff; andcross-linking the monomer solution to produce a filtration layer having a pore size of less than 5 microns.
  • 20. The method, as set forth in claim 19, wherein cross-linking the monomer solution comprises UV radiation.
  • 21. The method, as set forth in claim 19, wherein cross-linking the monomer solution comprises heat cross-linking.
  • 22. A medical device comprising: an inflatable balloon cuff;an endotracheal tube associated with the balloon cuff, wherein the endotracheal tube passes through an opening of the balloon cuff; anda filtration layer disposed on a tissue-contacting surface of the balloon cuff, wherein the filtration layer is adapted to filter out microbes from mucosal secretions.
  • 23. A method comprising: filtering out microbes from mucosal secretions before they enter the folds of an inflatable balloon cuff associated with an endotracheal tube, wherein the endotracheal tube passes through a proximal opening and a distal opening of the balloon cuff.
  • 24. The medical device, as set forth in claim 1, wherein the tracheal tube comprises an endotracheal tube.
  • 25. A medical device comprising: an inflatable balloon cuff;a tracheal tube associated with the balloon cuff, wherein the tracheal tube passes through an opening of the balloon cuff; anda filtration layer disposed on a tissue-contacting surface of the balloon cuff, wherein the filtration layer is adapted to filter out microbes from mucosal secretions.
US Referenced Citations (241)
Number Name Date Kind
2927584 Wallace Mar 1960 A
3769983 Merav Nov 1973 A
3810474 Cross May 1974 A
3822238 Blair et al. Jul 1974 A
3913565 Kawahara Oct 1975 A
3971385 Corbett Jul 1976 A
3975350 Hudgin et al. Aug 1976 A
3995643 Merav Dec 1976 A
4022217 Rowean May 1977 A
4106509 McWhorter Aug 1978 A
4130617 Wallace Dec 1978 A
4230108 Young Oct 1980 A
4231365 Scarberry Nov 1980 A
4235239 Elam Nov 1980 A
4340046 Cox Jul 1982 A
4569344 Palmer Feb 1986 A
4638539 Palmer Jan 1987 A
4649913 Watson Mar 1987 A
4696296 Palmer Sep 1987 A
4700700 Eliachar Oct 1987 A
4791920 Fauza Dec 1988 A
4825859 Lambert May 1989 A
4825861 Koss May 1989 A
4834726 Lambert May 1989 A
4836199 Palmer Jun 1989 A
4838255 Lambert Jun 1989 A
4850348 Pell et al. Jul 1989 A
4867153 Lorenzen et al. Sep 1989 A
4872579 Palmer Oct 1989 A
4886059 Weber Dec 1989 A
4927412 Menasche May 1990 A
4938741 Lambert Jul 1990 A
4963313 Noddin et al. Oct 1990 A
4967743 Lambert Nov 1990 A
4979505 Cox Dec 1990 A
5020534 Pell et al. Jun 1991 A
5021045 Buckberg et al. Jun 1991 A
5025806 Palmer et al. Jun 1991 A
5029580 Radford et al. Jul 1991 A
5033466 Weymuller, Jr. Jul 1991 A
5060646 Page Oct 1991 A
5065754 Jensen Nov 1991 A
5074840 Yoon Dec 1991 A
5076268 Weber Dec 1991 A
5098379 Conway et al. Mar 1992 A
5103816 Kirschbaum et al. Apr 1992 A
5107829 Lambert Apr 1992 A
5120322 Davis et al. Jun 1992 A
5122122 Allgood Jun 1992 A
5133345 Lambert Jul 1992 A
5135516 Sahatjian et al. Aug 1992 A
5137671 Conway et al. Aug 1992 A
5158569 Strickland et al. Oct 1992 A
5165420 Strickland Nov 1992 A
5176638 Don Michael Jan 1993 A
5190810 Kirschbaum et al. Mar 1993 A
5199427 Strickland Apr 1993 A
5201310 Turnbull et al. Apr 1993 A
5207643 Davis May 1993 A
5213576 Abiuso et al. May 1993 A
5215522 Page et al. Jun 1993 A
5218957 Strickland Jun 1993 A
5230332 Strickland Jul 1993 A
5233979 Strickland Aug 1993 A
5246012 Strickland Sep 1993 A
5250070 Parodi Oct 1993 A
5251619 Lee Oct 1993 A
5261896 Conway et al. Nov 1993 A
5263478 Davis Nov 1993 A
5269770 Conway et al. Dec 1993 A
5277177 Page et al. Jan 1994 A
5290585 Elton Mar 1994 A
5304121 Sahatjian Apr 1994 A
5331027 Whitbourne Jul 1994 A
5360402 Conway et al. Nov 1994 A
5370656 Shevel Dec 1994 A
5370899 Conway et al. Dec 1994 A
5374261 Yoon Dec 1994 A
5392787 Yoon Feb 1995 A
5397302 Weaver et al. Mar 1995 A
5407423 Yoon Apr 1995 A
5417671 Jackson May 1995 A
5423745 Todd et al. Jun 1995 A
5439457 Yoon Aug 1995 A
5443063 Greenberg Aug 1995 A
5447505 Valentine et al. Sep 1995 A
5451204 Yoon Sep 1995 A
5466231 Cercone et al. Nov 1995 A
5469864 Rosenblatt Nov 1995 A
5482740 Conway et al. Jan 1996 A
5484426 Yoon Jan 1996 A
5487730 Marcadis et al. Jan 1996 A
5494029 Lane et al. Feb 1996 A
5501669 Conway et al. Mar 1996 A
5507284 Daneshvar Apr 1996 A
5509899 Fan et al. Apr 1996 A
5524642 Rosenblatt Jun 1996 A
5545132 Fagan et al. Aug 1996 A
5556391 Cercone et al. Sep 1996 A
5593718 Conway et al. Jan 1997 A
5599292 Yoon Feb 1997 A
5599299 Weaver et al. Feb 1997 A
5599321 Conway et al. Feb 1997 A
5611336 Page et al. Mar 1997 A
5613950 Yoon Mar 1997 A
5649902 Yoon Jul 1997 A
5653229 Greenberg Aug 1997 A
5670111 Conway et al. Sep 1997 A
5674192 Sahatjian et al. Oct 1997 A
5693014 Abele et al. Dec 1997 A
5694922 Palmer Dec 1997 A
5697365 Pell Dec 1997 A
5700239 Yoon Dec 1997 A
5715815 Lorenzen et al. Feb 1998 A
5720726 Marcadis et al. Feb 1998 A
5722931 Heaven Mar 1998 A
5730123 Lorenzen Mar 1998 A
5733252 Yoon Mar 1998 A
5735271 Lorenzen et al. Apr 1998 A
5765559 Kim Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5810786 Jackson et al. Sep 1998 A
5819723 Joseph Oct 1998 A
5819733 Bertram Oct 1998 A
5827215 Yoon Oct 1998 A
5843017 Yoon Dec 1998 A
5843028 Weaver et al. Dec 1998 A
5843060 Cercone Dec 1998 A
5843089 Sahatjian et al. Dec 1998 A
5868719 Tsukernik Feb 1999 A
5908406 Ostapchenko Jun 1999 A
5951597 Westlund et al. Sep 1999 A
5954706 Sahatjian Sep 1999 A
5954740 Ravenscroft et al. Sep 1999 A
5971954 Conway et al. Oct 1999 A
5976072 Greenberg Nov 1999 A
5997503 Willis et al. Dec 1999 A
5997546 Foster et al. Dec 1999 A
6010480 Abele et al. Jan 2000 A
6012451 Palmer Jan 2000 A
6048332 Duffy et al. Apr 2000 A
6110192 Ravenscroft et al. Aug 2000 A
6120904 Hostettler et al. Sep 2000 A
6129547 Cise Oct 2000 A
6152136 Pagan Nov 2000 A
6169123 Cercone Jan 2001 B1
6210364 Anderson et al. Apr 2001 B1
6214895 Cercone Apr 2001 B1
6227200 Crump et al. May 2001 B1
6240321 Janke et al. May 2001 B1
6248088 Yoon Jun 2001 B1
6264631 Willis et al. Jul 2001 B1
6264633 Knorig Jul 2001 B1
6277089 Yoon Aug 2001 B1
6312421 Boock Nov 2001 B1
6322586 Monroe et al. Nov 2001 B1
6364856 Ding et al. Apr 2002 B1
6378521 Van Den Berg Apr 2002 B1
6394093 Lethi May 2002 B1
6395012 Yoon et al. May 2002 B1
6398266 Crump Jun 2002 B1
6409716 Sahatjian et al. Jun 2002 B1
6481436 Neame Nov 2002 B1
6494203 Palmer Dec 2002 B1
6524274 Rosenthal et al. Feb 2003 B1
6526977 Göbel Mar 2003 B1
6537194 Winkler Mar 2003 B1
6543451 Crump et al. Apr 2003 B1
6551272 Gobel Apr 2003 B2
6572813 Zhang et al. Jun 2003 B1
6584970 Crump et al. Jul 2003 B1
6588425 Rouns et al. Jul 2003 B2
6588427 Carlsen et al. Jul 2003 B1
6602218 Yoon Aug 2003 B2
6602219 Madsen et al. Aug 2003 B2
6609520 Carlsen et al. Aug 2003 B1
6612304 Cise et al. Sep 2003 B1
6612305 Fauza Sep 2003 B2
6613025 Palasis Sep 2003 B1
6615835 Cise et al. Sep 2003 B1
6620128 Simhambhatla Sep 2003 B1
6623450 Dutta Sep 2003 B1
6629530 Cise Oct 2003 B2
6632091 Cise et al. Oct 2003 B1
6651664 Lomholt Nov 2003 B1
6688306 Cise et al. Feb 2004 B1
6698424 Madsen et al. Mar 2004 B2
6705320 Anderson Mar 2004 B1
6722368 Shaikh Apr 2004 B1
6726696 Houser et al. Apr 2004 B1
6745773 Gobel Jun 2004 B1
6767340 Willis et al. Jul 2004 B2
6769430 Carlsen et al. Aug 2004 B1
6770066 Weaver et al. Aug 2004 B1
6786876 Cox Sep 2004 B2
6790221 Monroe et al. Sep 2004 B2
6796309 Nash et al. Sep 2004 B2
6802317 Göbel Oct 2004 B2
6805125 Crump et al. Oct 2004 B1
6808521 McMichael Oct 2004 B1
6814730 Li Nov 2004 B2
6890339 Sahatjian et al. May 2005 B2
6908449 Willis et al. Jun 2005 B2
6916307 Willis et al. Jul 2005 B2
6923786 Rouns et al. Aug 2005 B2
6997909 Goldberg Feb 2006 B2
7040321 Gobel May 2006 B2
7040322 Fortuna May 2006 B2
7066905 Squire et al. Jun 2006 B2
7098028 Holmes et al. Aug 2006 B2
7147252 Teuscher et al. Dec 2006 B2
7258120 Melker Aug 2007 B2
20020032407 Willis et al. Mar 2002 A1
20020082552 Ding et al. Jun 2002 A1
20020195110 Watton Dec 2002 A1
20030073625 Redman et al. Apr 2003 A1
20030116162 Madsen et al. Jun 2003 A1
20030225369 McMichael et al. Dec 2003 A1
20030225392 McMichael et al. Dec 2003 A1
20030225393 McMichael et al. Dec 2003 A1
20040079376 Melker Apr 2004 A1
20040106899 McMichael et al. Jun 2004 A1
20040106900 Triebes et al. Jun 2004 A1
20040106901 Letson et al. Jun 2004 A1
20040116898 Hawk Jun 2004 A1
20040154623 Schaeffer et al. Aug 2004 A1
20040193100 Van Hooser et al. Sep 2004 A1
20040193101 Van Hooser et al. Sep 2004 A1
20040215142 Matheis et al. Oct 2004 A1
20040221853 Miller Nov 2004 A1
20040255951 Grey Dec 2004 A1
20050004560 Cox Jan 2005 A1
20050033267 Decaria Feb 2005 A1
20050033268 Decaria Feb 2005 A1
20050033269 Decaria Feb 2005 A1
20050038381 McMichael Feb 2005 A1
20050065468 Goebel Mar 2005 A1
20050124932 Foster et al. Jun 2005 A1
20050124935 McMichael Jun 2005 A1
20050137619 Schewe et al. Jun 2005 A1
20050166924 Thomas et al. Aug 2005 A1
Foreign Referenced Citations (16)
Number Date Country
2353007 Jun 2000 CA
19500550 Jul 1996 DE
19855521 Jun 2000 DE
0884061 Jun 1998 EP
1267981 Apr 2000 EP
1005877 Jun 2000 EP
1135184 Jun 2000 EP
2168256 Jun 1986 GB
WO 9522367 Aug 1995 WO
WO 0027461 May 2000 WO
WO 0032262 Jun 2000 WO
WO 0032263 Jun 2000 WO
WO 03045487 Jun 2003 WO
WO 2004067262 Aug 2004 WO
WO 2004101046 Nov 2004 WO
WO 2006023486 Mar 2006 WO
Related Publications (1)
Number Date Country
20080142016 A1 Jun 2008 US